NVSEF News and Press, Novartis Ag Basel Akt From 09/19/23

2023-09-19 06:58:00 ET More on BeiGene, Novartis, etc. Sales Success Comes With Side Effects For Drug Maker BeiGene Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis shareholders approve 100...

2023-09-18 15:20:36 ET Summary Initiation of the pivotal OPERA-01 study, using palazestrant for the treatment of 2nd-line/3rd-line HR+/HER2- metastatic breast cancer patients, expected in Q4 of 2023. Monotherapy results from the phase 2 study, using palazestrant for the treatment ...

2023-09-16 08:26:36 ET Summary The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. IXJ: a global alternative to ...

2023-09-11 11:49:04 ET Summary Bayer's stock has had a volatile performance, reaching highs and lows since December 2022, when I first wrote about this company. Both from a relative and intrinsic standpoint, Bayer seems to be severely undervalued. Bayer has both short-ter...

2023-09-11 08:49:41 ET More on Bausch + Lomb Seeking Alpha’s Quant Rating on Bausch + Lomb Historical earnings data for Bausch + Lomb Financial information for Bausch + Lomb Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease Bausch +...

2023-09-11 08:20:32 ET More on Marker Financial information for Marker Therapeutics For further details see: Marker gains as lymphoma therapy leads to complete remission

2023-09-06 10:21:15 ET More on AbbVie, Novartis, etc. AbbVie: Proving The Bears Wrong Again As Shares Surged AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued AbbVie: Balance Is Everything AbbVie: Still A Buy According To Buffett's 10xEBT Rule A...

2023-09-05 08:27:58 ET Summary Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Biogen's acquisition of Reata Pharmaceuticals brings the potential for significant sales growth with SKYCLARYS, a drug for Friedreich...

2023-09-03 12:00:00 ET More on Medicare pricing negotiations Wall Street lists potential targets for Medicare drug price negotiations Analysts rule out major industry impact from drug pricing negotiations J&J, Merck, Regeneron most exposed to Medicare drug price ...

2023-08-29 07:45:20 ET The Centers for Medicare and Medicaid Services (CMS) announced on Tuesday the first 10 Medicare Part D drugs it selected for pricing negotiations, a provision introduced as part of last year's Inflation Reduction Act. The list includes Eliquis , a blood thinne...